Thermo Fisher Unveils DynaDrive 5L Single-Use Bioreactor, Enabling Seamless 1L to 5,000L Scale-Up for Biologics Manufacturing

August 2, 2026

Constancy Researchers USA

Overview

Thermo Fisher Scientific has launched its DynaDrive 5L single-use bioreactor, designed to enhance workflow efficiency in biopharmaceutical manufacturing. This new system facilitates seamless culture scale-up from 1L to an impressive 5,000L, directly addressing critical production bottlenecks. The introduction comes as growing biopharmaceutical pipelines, particularly in cell and gene therapy, drive substantial demand for advanced bioreactor solutions from key players like Cytiva.

In Depth

Key Findings

Thermo Fisher Scientific has introduced its innovative DynaDrive 5L single-use bioreactor, significantly advancing biopharmaceutical manufacturing capabilities. This new system enables seamless culture scale-up from 1L to 5,000L, offering unparalleled flexibility and efficiency for complex biologics production, especially in the rapidly expanding cell and gene therapy sectors. The launch underscores a clear industry trend towards high-capacity, single-use solutions to meet escalating demand.

Technical / Clinical Details

Seamless Scalability: The DynaDrive 5L bioreactor is engineered to support a broad range of culture volumes, from 1 liter to 5,000 liters, simplifying the transition from process development to commercial-scale manufacturing. This capability is critical for reducing development timelines and costs associated with bringing new biologics to market.
Enhanced Workflow Efficiency: Leveraging single-use technology eliminates the need for time-consuming cleaning and sterilization cycles, thereby accelerating manufacturing processes and substantially mitigating contamination risks. This operational advantage is particularly vital for the production of high-value cell and gene therapy products.
Portfolio Expansion: This addition fortifies Thermo Fisher Scientific’s bioreactor portfolio, providing customers with a more comprehensive suite of solutions tailored to diverse bioprocessing needs, from upstream cell culture to downstream purification.

Background & Context

The biopharmaceutical industry is experiencing robust growth, driven by a burgeoning pipeline of novel therapies, with cell and gene therapies at the forefront. The inherent complexities and stringent quality requirements of manufacturing these advanced modalities necessitate highly efficient and scalable production technologies. According to Constancy Researchers, the market for bioreactors is being propelled by increased demand in biologics manufacturing and the growing output of cell and gene therapy products. Competitors such as Cytiva are also heavily investing in single-use portfolios, process intelligence, and scalable manufacturing solutions to capitalize on these market dynamics.

Strategic Significance & Outlook

The evolution of single-use bioreactor technology is pivotal for the successful commercialization of biopharmaceuticals, especially in the cell and gene therapy arena. By improving manufacturing flexibility and efficiency, these advancements increase the accessibility of innovative treatments to a wider patient population. Future developments are expected to integrate further process intelligence and automation, continually shaping the landscape of biopharmaceutical manufacturing and accelerating the delivery of life-saving medicines.

Source: https://constancyresearchers.com/press_release/bioreactors-market-biologics-manufacturing-demand-and-cell-and-gene-therapy-production-to-drive-market-growth/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.